TrialJournal of neuro-oncology2016

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Shiao-Pei Weathers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.